정부 R&D 지원의 기업 R&D 투자에 대한 효과 분석 -제약산업을 중심으로-
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 사공진 | - |
dc.contributor.author | 신유원 | - |
dc.date.accessioned | 2021-06-23T14:04:11Z | - |
dc.date.available | 2021-06-23T14:04:11Z | - |
dc.date.created | 2021-01-22 | - |
dc.date.issued | 2010-03 | - |
dc.identifier.issn | 1225-4266 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/40319 | - |
dc.language | 한국어 | - |
dc.language.iso | ko | - |
dc.publisher | 한국보건행정학회 | - |
dc.title | 정부 R&D 지원의 기업 R&D 투자에 대한 효과 분석 -제약산업을 중심으로- | - |
dc.title.alternative | An Analysis on the Effect of the Government R&D Subsidies on the Private R&D Investments : in the Case of the Pharmaceutical Industry | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | 사공진 | - |
dc.identifier.bibliographicCitation | 보건행정학회지, v.20, no.1, pp.183 - 203 | - |
dc.relation.isPartOf | 보건행정학회지 | - |
dc.citation.title | 보건행정학회지 | - |
dc.citation.volume | 20 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 183 | - |
dc.citation.endPage | 203 | - |
dc.type.rims | ART | - |
dc.identifier.kciid | ART001430465 | - |
dc.description.journalClass | 2 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordAuthor | pharmaceutical industry | - |
dc.subject.keywordAuthor | government R& | - |
dc.subject.keywordAuthor | D subsidies | - |
dc.subject.keywordAuthor | private R& | - |
dc.subject.keywordAuthor | D investments | - |
dc.identifier.url | https://kiss.kstudy.com/Detail/Ar?key=3135676 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
55 Hanyangdeahak-ro, Sangnok-gu, Ansan, Gyeonggi-do, 15588, Korea+82-31-400-4269 sweetbrain@hanyang.ac.kr
COPYRIGHT © 2021 HANYANG UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.